Physician profile
Roger David Mize
NPI 1265439574
$4,845.26
in general payments reported to CMS, 2019-2025
36 companies · $14.28 in 2025
The $14.28 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $382 · 2021: $1,711 · 2022: $1,094 · 2023: $647 · 2024: $299 · 2025: $14.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $751.78 | 2021 | |
| Abbvie INC. | $558.04 | 2021-2024 | |
| Novo Nordisk INC | $486.22 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $304.76 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $282.12 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.67 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $240.48 | 2019-2024 | |
| Pfizer INC. | $203.56 | 2019-2022 | |
| Glaxosmithkline, LLC. | $196.11 | 2020-2023 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $169.50 | 2019-2022 | |
| Astellas Pharma US INC | $156.70 | 2023-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $120.52 | 2021-2023 | |
| Amgen INC. | $119.72 | 2019-2024 | Otezla, Repatha |
| Lilly USA, LLC | $119.68 | 2019-2023 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $117.25 | 2019-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Mize listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.